Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R4-RA: Rituximab versus Tocilizumab in anti-TNF inadequate responders with rheumatoid arthritis
NL-OMON46338Phase 3Withdrawn
- Sponsor
- Queen Mary University of London
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rheumatoid arthritis (RA) comparing Rituximab with Tocilizumab (2 arms). Primary endpoint: Clinical Disease Activity Index response at 16 weeks. Planned start Sep 2016; status: withdrawn.
02
Drugs
rituximabtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON46338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46338.